Corporate Banner
Satellite Banner
Technology Networks Header
Tuesday, November 25, 2014
Technology Networks
 
Register | Sign in
Home Page > Videos > Bio-Rad Droplet Digital™ PCR and Organ Transplant Rejection
  Videos

Return

Bio-Rad Droplet Digital™ PCR and Organ Transplant Rejection
Bio-Rad Laboratories

Researchers at Chronix Biomedical applied Bio-Rad's ddPCR™ technology to quantify graft-derived cell-free DNA (cfDNA) in recent liver transplant patients and in stable patients who had undergone a transplant procedure more than six months earlier. ddPCR technology allowed Chronix to develop a fast and cost-effective laboratory test to detect cfDNA released into the blood stream by dying cells from the transplanted organ.

Sequencing methods typically require batch sampling, but using ddPCR assays, researchers are able to run single samples. Additionally, this method reduces test time from three days or more to one day, and reduces costs by 90 percent. The study authors were able to address the need for donor DNA by preselecting single-nucleotide polymorphisms (SNPs) that ensure enough heterogeneity between donor and recipient. The new blood test can also deliver results up to several days earlier than the conventional aspartate aminotransferase (AST) and bilirubin tests for liver transplantation rejection, with the potential for an immediate positive impact on patient care.

Chronix Biomedical is a molecular diagnostics company developing blood tests primarily for cancer, including companion diagnostics and tests for detecting minimal residual disease. Chronix is preparing to offer its pioneering tests through its own laboratories under CLIA certification in North America and the CE mark in Europe. The Company's initial product is a test to be used by cancer treatment centers and oncologists in the treatment of breast cancer patients. Chronix is privately held with headquarters in San Jose, California, and laboratories in Göttingen, Germany and Brookings, South Dakota.

The Droplet Digital PCR system enables the quantification of target DNA with unrivaled precision by partitioning samples into 20,000 nanoliter-sized droplets. After PCR on a thermal cycler, PCR-positive and PCR-negative droplets are counted to provide absolute quantification of the target DNA. The QX200™ system, Bio-Rad's second-generation digital PCR system, provides absolute quantification of target DNA or RNA molecules using EvaGreen or TaqMan hydrolysis probes, yielding unmatched sensitivity and precision for a wide variety of applications.

Request more information
Company product page



For access to this article, enter your email address to instantly recieve a Password Reset link.

Please enter your email address below:

Existing users please Sign In here. Don't have an account? Register Here for free access.

Don't have an account? | Register Here

Scientific News
Monitoring Effectiveness Of Hay Fever Immunotherapy
A new test for measuring histamine release from certain white blood cells could help doctors monitor the effectiveness of immunotherapy for hay fever.
Developing a Noninvasive Test for Endometriosis
UCSF researchers identify patterns of genetic activity that could help in early detection of disorder.
Test Detects Early Brain Damage in Football Players
New Contrast-Enhanced MRI Developed by BGU Visualizes Brain Injury in the Blood-Brain Barrier Offering Significant Diagnostic Capabilities.
New Test Developed at Dana-Farber/Brigham and Women's Cancer Center
Rapid Heme Panel - A high-tech genetic test that speeds treatment decisions for blood cancer patients.
Urgent Need for Fast Dx to Help Tackle Antibiotic Resistance
£10 million Longitude Prize for an accurate, rapid, cost-effective and easy-to-use point-of-need diagnostic test for bacterial infections.
Test Developed To Rapidly Diagnose Bloodstream Infection
New technology can detect bacterial invaders with unprecedented speed and sensitivity.
Classification of Gene Mutations in Neuroblastoma
Penn Medicine and CHOP experts define riskier mutations in neuroblastoma, setting stage for clinical trial.
New Genetic Cause of Epilepsy Identified
San Diego girl improves after discovery of DNA mutation tied to potassium regulation.
Cancer Cell Fingerprints in the Blood May Speed up Childhood Cancer Diagnosis
Researchers found unique molecular fingerprints for 11 types of children’s tumours, to develop blood tests to diagnose these cancers.
Blood Test Developed to Diagnose Early Onset Alzheimer’s Disease
New blood-test could predict a person’s risk of developing AD much earlier than is currently possible.
Scroll Up
Scroll Down
Skyscraper Banner
SELECTBIO Market Reports
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Go to LabTube.tv